The sale is small relative to the fund's likely total holdings and appears to be a routine partial exit by a pre-IPO investor. Monitor for any follow-on Form 4 filings or larger 144s from the same fund that could signal a broader distribution.
Price Chart
Executive Summary
Qiming Managing Directors Fund VI, L.P., a pre-IPO venture investor in Alamar Biosciences, filed a Form 144 on October 14, 2026, indicating intent to sell 41,945 shares of common stock with an approximate market value of $987,000. The shares were acquired through private placements in Series A-3, A-4, and B preferred stock that converted upon the IPO. This is a relatively small sale relative to the fund's likely total position and does not signal a change in fundamental outlook.
Key Facts
- Qiming Managing Directors Fund VI, L.P. filed Form 144 to sell 41,945 shares of Alamar Biosciences common stock.
- Estimated aggregate market value of the proposed sale is approximately $987,000.
- Shares were acquired via private investments in Series A-3, A-4, and B preferred stock that converted to common upon the IPO.
- The sale is to be executed through J.P. Morgan Securities LLC.
- The filing date is October 14, 2026, and the proposed sale plan date is also October 14, 2026.
Financial Impact
Proposed sale of ~$987,000 in ALMR common stock by a venture investor.
Risk Factors
- Insider selling, even small, can create negative sentiment in a thinly traded stock.
- The fund may file additional 144s in the future, increasing selling pressure.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001231919-26-001454 |
| Document: 0001231919-26-001454-index.html | 0001231919-26-001454 |
| Document: 0001231919-26-001454.txt | 0001231919-26-001454 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (+11.93%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.69 (−4.87%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.69 (−6.43%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.69 (+0.66%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.69 (−16.08%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.69 (+12.01%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.69 (+7.99%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.69 (+28.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers